Literature DB >> 2200384

Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Black Hypertension Quality of Life Multicenter Trial Group.

S H Croog1, B W Kong, S Levine, M R Weir, R M Baume, E Saunders.   

Abstract

A multicenter, randomized double-blind clinical trial was conducted among 306 black men and women with mild to moderate hypertension to determine effects of atenolol, captopril, and verapamil SR on measures of quality of life. Patients were randomly assigned to a stable or forced-dose titration sequence. After an 8-week treatment period, the rate of withdrawal from treatment because of adverse effects was low and did not differ by drug treatment group or titration level. Patients taking verapamil SR showed a significantly greater reduction in mean blood pressures than patients treated with atenolol or captopril. Along with absence of worsening on any quality of life total scale scores examined over the treatment period, we found either improvement or no change in the total scale scores for all three treatment groups. Among both male and female patients, comparisons between drug treatment groups showed no differences in degree of change on the total scale scores. In comparisons within each treatment group, improvement in scores of male patients after 8 weeks appeared among those taking atenolol in general well-being and physical symptoms reduction; among male patients taking captopril in general well-being, physical symptoms, and sexual performance; and among male patients receiving verapamil SR in scores in irritability, sleep, and the Digit Span test. Improvement in scores among female patients taking atenolol was found in scores on general well-being, physical symptoms, and sleep; among women taking captopril on general well-being, physical symptoms, and irritability; and among women taking verapamil SR on general well-being. Patients in all treatment groups improved on measures of visuomotor functioning. The research shows that with the three newer generation antihypertensive medications studied, blood pressure control was achieved during the treatment period without negative effects on quality of life scales, along with findings of improvement on some measures. Given the special clinical features of hypertension in black patients, the study underlines as well the potential and utility of systematic tracking of measures of quality of life, while monitoring blood pressures in this patient population.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2200384     DOI: 10.1001/archinte.150.8.1733

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  20 in total

1.  Association between lower digit symbol substitution test score and slower gait and greater risk of mortality and of developing incident disability in well-functioning older adults.

Authors:  Caterina Rosano; Anne B Newman; Ronit Katz; Calvin H Hirsch; Lewis H Kuller
Journal:  J Am Geriatr Soc       Date:  2008-08-05       Impact factor: 5.562

2.  Validity and reliability of the Spanish version of the Psychological General Well-Being Index.

Authors:  X Badia; F Gutiérrez; I Wiklund; J Alonso
Journal:  Qual Life Res       Date:  1996-02       Impact factor: 4.147

Review 3.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 4.  Evaluation of quality of life for diverse patient populations.

Authors:  K R Yabroff; B P Linas; K Schulman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 5.  Health-related quality-of-life measurement in hypertension. A review of randomised controlled drug trials.

Authors:  I Côté; J P Grégoire; J Moisan
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

6.  Quality of life evaluation of antihypertensive drugs.

Authors:  C J Bulpitt; A E Fletcher
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

7.  Functional genetic variation in aminopeptidase A (ENPEP): lack of clear association with focal and segmental glomerulosclerosis (FSGS).

Authors:  Stephen Tonna; Savita V Dandapani; Andrea Uscinski; Gerald B Appel; Johannes S Schlöndorff; Kang Zhang; Bradley M Denker; Martin R Pollak
Journal:  Gene       Date:  2007-12-03       Impact factor: 3.688

Review 8.  A critical review of dimension-specific measures of health-related quality of life in cross-cultural research.

Authors:  M J Naughton; I Wiklund
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

9.  A new antihypertensive strategy for black patients: low-dose multimechanism therapy.

Authors:  E Saunders; J Neutel
Journal:  J Natl Med Assoc       Date:  1996-03       Impact factor: 1.798

Review 10.  Quality of life in the treatment of hypertension. The effect of calcium antagonists.

Authors:  A Fletcher; C Bulpitt
Journal:  Drugs       Date:  1992       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.